The company is trading up since yesterday’s close of $196.38. Shares are trading at $198.33 just above the 50 day moving average which is $190.01 and a tad above the 200 day moving average of $181.27. The 50 day moving average moved up $8.53 and the 200 day average was up $17.27.
Becton, Dickinson and Company (NYSE:BDX) has been the object of insider selling activity recently. Jeffrey S. Sherman, Sr VP disclosed the sale of 28,765 shares of BDX stock. The shares were purchased at an average price of $185.98. Sherman now owns $4,109,042 of the stock per the Form 4 SEC filing. Jeffrey S. Sherman, Sr VP reported the sale of 31,464 shares. The shares were sold on February 15th for an average price of $180.03. The Sr VP now owns $3,977,583 of the stock according to the SEC filing.
Alexandre Conroy, EVP disclosed the sale of 8,500 shares of (BDX). The shares were sold on February 14th for an average price of $177.86. Conroy now owns $4,211,013 of the stock per the Form 4 SEC filing.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Business’s subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A..
These firms have also modified their investment in BDX. Piedmont Investment Advisors LLC augmented its stake by buying 384 shares an increase of 0.9%. Piedmont Investment Advisors LLC now controls 44,389 shares worth $8,143,000. The value of the position overall is up by 11.8%. As of quarter end Phh Investments, Ltd. had disposed of 60 shares trimming its position 0.9%. The value of the company’s investment in Becton, Dickinson and Company increased from $1,164,000 to $1,237,000 increasing 6.3% for the reporting period.
Ballentine Partners, LLC cut its ownership by selling 480 shares a decrease of 73.8% in the quarter. Ballentine Partners, LLC owns 170 shares with a value of $31,000. The total value of its holdings decreased 73.5%. Empire Life Investments Inc. trimmed its holdings by selling 12,419 shares a decrease of 14.7% as of 03/31/2017. Empire Life Investments Inc. currently owns 72,182 shares valued at $13,241,000. The total value of its holdings decreased 1.1%.
On June 30 the company was upgraded from “Strong Buy” to “Strong Buy” in a statement from Raymond James. On September 23 the stock rating was downgraded to “Sell” from “Neutral” and a price target of $165.00 was set by analysts at Citigroup.
Citigroup both downgraded the stock and raised the price target on September 23 changing the price objective from $146.00 to $165.00 and setting the rating at “Sell” which had previously been “Neutral”. On February 11 the company was upgraded to “Buy” from “Hold” by Deutsche Bank.
February 4 investment analysts at Citigroup maintained a company rating of “Neutral” but lowered the price target to $146.00 from $153.00. On January 6 the stock rating was downgraded from “Buy” to “Hold” in a report issued by Evercore ISI Group.
The company also declared a dividend that was paid on Fri Jun 30, 2017. The dividend payment was $0.730 per share for the quarter which comes to $2.92 on an annualized basis. The dividend yield was $1.48. The ex-dividend date was Wednesday the 7th of June 2017.
The most current P/E ratio is 32.97 and the market cap is 42.35B. As of the last earnings report the EPS was $6.02 and is projected to be $9.44 for the current year with 213,305,000 shares now outstanding. Next quarter’s EPS is estimated at $2.38 and the next full year EPS is anticipated to be $10.36.